Recordati stock enters final takeover phase before delisting
Published on 11/17/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTakeover Sets Recordati's Next Steps
- The CVC and GBL-backed bidder holds 91.923 percent of Recordati's share capital after the reopened offer.
- Payment for shares tendered during the reopening is scheduled for November 17, followed by the squeeze-out procedure.
- Recordati's board decided not to distribute the planned 2026 interim dividend.
Recordati's takeover entered its final phase on November 13, when Respighi BidCo and its CVC and GBL backers reported a 91.923 percent stake in the Italian pharmaceutical group. In its company release, Recordati said payment for shares tendered during the reopened offer is scheduled for November 17, while the remaining shares are to be acquired through the joint procedure that will lead to delisting.
Respighi BidCo will purchase the remaining shares at the cash offer price of 53.00 euros per share. The transaction follows the reopened tender period, which lifted the bidder's holding above the level required to pursue the squeeze-out and remove Recordati shares from Euronext Milan.
Delisting Becomes The Next Corporate Step
The scheduled delisting separates two dates that matter to minority shareholders. Investors who tendered shares during the reopening are due to receive the offer consideration on November 17. The subsequent joint purchase procedure is scheduled to transfer the remaining shares to the bidder and make the delisting effective on November 24.
The transaction also changes Recordati's ownership structure. The company said that, following settlement of the offer, it became subject to the management and coordination of Respighi TopCo, replacing Rossini Luxembourg in that role. The process leaves minority shareholders focused on the cash settlement and the final removal of the shares from the Milan market.
Growth Targets Remain In Place
The takeover process follows a strong first nine months operationally. Recordati reported consolidated revenue of 2,103.7 million euros for the first nine months of 2026, up 7.5 percent from the comparable period. EBITDA rose 7.7 percent to 801.1 million euros, while adjusted net income increased 6.4 percent to 524.9 million euros.
Rare Diseases remained the main growth engine, with revenue of 928.2 million euros, an increase of 18.7 percent. Specialty and Primary Care revenue edged up 0.5 percent to 1,135.5 million euros. Management confirmed the full-year 2026 targets at the upper end of the guidance ranges, including revenue of 2,730 million to 2,800 million euros, EBITDA of 995 million to 1,030 million euros and adjusted net income of 655 million to 685 million euros.
Recordati's board also decided not to distribute the planned 2026 interim dividend. The company said the 53.00-euro offer price is cum dividend, so an interim payment would not have changed the economic consideration for minority shareholders during the takeover process.
Recordati Stock At Lang & Schwarz
Recordati stock traded at 52.93 euros on Lang & Schwarz at 11:03 CET on Tuesday, November 17.
Recordati S.p.A.
- Company: Recordati S.p.A.
- ISIN: IT0003828271
- Exchange: Euronext Milan
- Offer price: 53.00 euros per share
- Offer stake: 91.923 percent of share capital
- Scheduled delisting: November 24, 2026
Italian equities trade against the backdrop of the FTSE MIB.
For further coverage, see More news and analyses on Recordati stock.
